Cardioplegia
- PMID: 32119350
- Bookshelf ID: NBK554463
Cardioplegia
Excerpt
Cardioplegia is a pharmacological therapy administered during cardiac surgery to intentionally and temporarily arrest the heart. The first solution used during cardiopulmonary bypass was reported by Dr. Melrose in the early 1950s, who identified that high levels of potassium citrate induced a reversible cardiac arrest. An influx of potassium depolarizes the myocardial membrane causing contraction and thus release and subsequent sequestration of calcium ions resulting in a diastolic arrest. The resting membrane potential in myocytes is about -85 mV, and with the influx of sodium ions, depolarization occurs (membrane becomes more positive -45 to -30 mV) and thus generating an action potential that is potentiated by L-type calcium channels. These voltage-gated channels are targeted with cardioplegia to induce cardiac arrest. The persistence of potassium reduces the membrane potential and does not allow for adequate repolarization. This, in turn, creating a diastolic cardiac arrest. As the solution diffuses and there is a washout of its components along with products of anaerobic cellular metabolism, electrical activity begins to appear, and redosing of cardioplegia is required if clinically indicated. Potassium, however, is not the only ion commonly found in cardioplegia. Other ions such as calcium, sodium, and magnesium all participate in reducing contractility and preserving the myocardium. Additionally, components such as lidocaine, bicarb, and even glucose may be added for further protection.
Cardioplegia is an essential component of cardiopulmonary bypass and with the primary goal to reduce myocardial oxygen demand by creating electrical quiescence and cooling the heart to reduce the ischemic effects of being on bypass. The use of cardioplegia, in addition to being cardioprotective, also provides a relatively bloodless and motionless surgical field. There are many forms of cardioplegia ranging from the location of administration retrograde vs. antegrade as well as varying components within the solution, temperature, indications, adverse effects, pharmacokinetics, and pharmacodynamics.
Copyright © 2025, StatPearls Publishing LLC.
Conflict of interest statement
Sections
Similar articles
-
Myocardial function after polarizing versus depolarizing cardiac arrest with blood cardioplegia in a porcine model of cardiopulmonary bypass.Eur J Cardiothorac Surg. 2016 Jul;50(1):130-9. doi: 10.1093/ejcts/ezv488. Epub 2016 Feb 2. Eur J Cardiothorac Surg. 2016. PMID: 26843432 Free PMC article.
-
Warm Blood Cardioplegia.2023 Jun 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jun 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32644345 Free Books & Documents.
-
Feasibility and safety of continuous retrograde administration of Del Nido cardioplegia: a case series.J Cardiothorac Surg. 2015 Nov 26;10:176. doi: 10.1186/s13019-015-0383-x. J Cardiothorac Surg. 2015. PMID: 26612068 Free PMC article.
-
Cardioplegia and cardiac surgery: pharmacological arrest and cardioprotection during global ischemia and reperfusion.Pharmacol Ther. 2010 Jul;127(1):41-52. doi: 10.1016/j.pharmthera.2010.04.001. Epub 2010 Apr 14. Pharmacol Ther. 2010. PMID: 20398698 Review.
-
The physiologic basis of warm cardioplegia.Ann Thorac Surg. 1995 Sep;60(3):819-23. doi: 10.1016/0003-4975(95)00422-H. Ann Thorac Surg. 1995. PMID: 7677540 Review.
References
-
- Chambers DJ, Fallouh HB. Cardioplegia and cardiac surgery: pharmacological arrest and cardioprotection during global ischemia and reperfusion. Pharmacol Ther. 2010 Jul;127(1):41-52. - PubMed
-
- Katayama O, Amrani M, Ledingham S, Jayakumar J, Smolenski RT, Severs N, Rothery S, Yacoub MH. Effect of cardioplegia infusion pressure on coronary artery endothelium and cardiac mechanical function. Eur J Cardiothorac Surg. 1997 Apr;11(4):751-62. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Medical
Research Materials